Nuvectis Pharma Files 2023 Annual Report on Form 10-K

TL;DR

<b>Nuvectis Pharma, Inc. has filed its 2023 10-K, outlining financial details and corporate events including stock grants and market agreements.</b>

AI Summary

Nuvectis Pharma, Inc. (NVCT) filed a Annual Report (10-K) with the SEC on March 5, 2024. Nuvectis Pharma, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The filing details the company's financial performance and business operations. Key dates mentioned include the IPO on 2022-02-08 and various stock and RSU grants to executives. The company entered into an At-Market Agreement on 2023-03-17 and again on 2023-12-31. Subsequent events include RSU grants on 2024-01-04 to key personnel.

Why It Matters

For investors and stakeholders tracking Nuvectis Pharma, Inc., this filing contains several important signals. This 10-K provides investors with a comprehensive overview of Nuvectis Pharma's financial health and strategic activities for the 2023 fiscal year. The filing includes details on executive compensation, stock awards, and financing agreements, which are crucial for understanding shareholder value and future capital structure.

Risk Assessment

Risk Level: medium — Nuvectis Pharma, Inc. shows moderate risk based on this filing. The company is in the pharmaceutical sector, which is inherently high-risk due to long development cycles, regulatory hurdles, and clinical trial failures, as evidenced by the numerous stock and RSU grants which often accompany early-stage biotech development.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to assess the company's current financial position and future prospects.

Executive Compensation

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period)
• 2024-03-05 — Filing Date (Date of submission)
• 2022-02-08 — IPO Date (Initial Public Offering)
• 2023-03-17 — At-Market Agreement Date (Financing agreement)
• 2024-01-04 — Subsequent RSU Grant Date (Executive compensation event)

Key Players & Entities

• Nuvectis Pharma, Inc. (company) — Filer name
• NVCT (company) — Ticker symbol
• 2023-12-31 (date) — Fiscal year end
• 2024-03-05 (date) — Filing date
• 2022-02-08 (date) — IPO date
• Mr. Shay Shemesh (person) — Recipient of stock grants
• Dr. Enrique Poradosu (person) — Recipient of stock grants
• Mr. Ron Bentsur (person) — Recipient of stock grants

FAQ

Risk Factors

• At-Market Agreements [medium — financial]: The company entered into At-Market Agreements in March 2023 and December 2023, which allow for the sale of common stock, potentially diluting existing shareholders.

Key Financial Figures

• $0.00001 — ch registered Common Stock, par value $0.00001 per NVCT NASDAQ Capital Market Se
• $8.57 — ion, based on the closing sale price of $8.57 as quoted by the Nasdaq Stock Market as

Filing Documents

• tmb-20231231x10k.htm (10-K) — 1352KB
• tmb-20231231xex4d6.htm (EX-4.6) — 7KB
• tmb-20231231xex19d1.htm (EX-19.1) — 114KB
• tmb-20231231xex21d1.htm (EX-21.1) — 1KB
• tmb-20231231xex23d1.htm (EX-23.1) — 7KB
• tmb-20231231xex31d1.htm (EX-31.1) — 10KB
• tmb-20231231xex31d2.htm (EX-31.2) — 10KB
• tmb-20231231xex32d1.htm (EX-32.1) — 6KB
• tmb-20231231xex32d2.htm (EX-32.2) — 6KB
• tmb-20231231xex97d1.htm (EX-97.1) — 65KB
• tmb-20231231x10k001.jpg (GRAPHIC) — 4KB
• tmb-20231231xex23d1003.jpg (GRAPHIC) — 4KB
• 0001558370-24-002497.txt (&nbsp;) — 6171KB
• tmb-20231231.xsd (EX-101.SCH) — 50KB
• tmb-20231231_cal.xml (EX-101.CAL) — 34KB
• tmb-20231231_def.xml (EX-101.DEF) — 202KB
• tmb-20231231_lab.xml (EX-101.LAB) — 398KB
• tmb-20231231_pre.xml (EX-101.PRE) — 351KB
• tmb-20231231x10k_htm.xml (XML) — 774KB

Business

Business 6 Item 1A.

Risk Factors

Risk Factors 17 Item 1B. Unresolved Staff Comments 44 Item 1C. Cybersecurity 44 Item 2.

Properties

Properties 46 Item 3.

Legal Proceedings

Legal Proceedings 46 Item 4. Mine Safety Disclosures 46 PART II 46 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 46 Item 6. [Reserved] 48 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 49 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 55 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 55 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 55 Item 9A.

Controls and Procedures

Controls and Procedures 55 Item 9B. Other Information 56 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 56 PART III 57 Item 10. Directors, Executive Officers and Corporate Governance 57 Item 11.

Executive Compensation

Executive Compensation 57 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 57 Item 13. Certain Relationships and Related Transactions, and Director Independence 57 Item 14. Principal Accountant Fees and Services 57 PART IV 58 Item 15. Exhibits and Financial Statement Schedules 58 Item 16. Form 10-K Summary 69 2 Table of Contents SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS Certain matters discussed in this report may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended (the "Securities Act") and the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. The words "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "would," "potential," "continue," "anticipate," "believe," "estimate," "may," "expect" and similar expressions are generally intended to identify forward-looking statements. These forward-looking statements are based on management's current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation, those discussed under the captions "Risk Factors," and elsewhere in this report. All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by these cautionary statements. Such forward-looking statements include, but are not limited to, statements about: expectations for inc

Business

Item 1. Business OVERVIEW We are a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. We seek to develop drug candidates in the precision medicine space, and our processes for selection and clinical development of drug candidates is based on scientific insights into cancer-promoting factors, as well as on our understanding of the clinical landscape and regulatory requirements. CORPORATE INFORMATION We were incorporated in July 2020 under the laws of the State of Delaware under the name Centry Pharma, Inc., and changed our name to Nuvectis Pharma, Inc. in July 2021. Our office is located at 1 Bridge Plaza, 2 nd Floor, Fort Lee, NJ 07024, and our telephone number is (201) 614-3150. We maintain a website with the address www.nuvectis.com. We make available free of charge through our website our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, and any amendments to these reports, as soon as reasonably practicable after we electronically file such material with, or furnish such material to, the Securities and Exchange Commission ("SEC"). We are not including the information on our website as a part of, nor incorporating it by reference into, this report. Additionally, the SEC maintains a website that contains annual, quarterly, and current reports, proxy statements, and other information that issuers (including us) file electronically with the SEC. The SEC's website address is http://www.sec.gov. PRODUCTS UNDER DEVELOPMENT NXP800 In May 2021, we licensed exclusive worldwide commercial rights to NXP800, a novel small molecule that exerts its biologic activity through activation of the kinase general control nonderepressible 2 ("GCN2"), and was discovered at the Institute for Cancer Research ("ICR") in London, England. Our license agreement with the ICR is subject to certain milestone and royalty

View Full Filing

View this 10-K filing on SEC EDGAR